BridgeBio Pharma, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
BridgeBio Pharma is a biopharmaceutical company that discovers and develops treatments for genetic diseases and cancers driven by specific molecular pathways, advancing a pipeline of drug candidates through its network of affiliated companies, including therapies for conditions like transthyretin amyloidosis.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Kumar NeilChief Executive Officer | Sell | $602K | 8,721at $69.01 | Sep 17, 2026 |
| Kumar NeilChief Executive Officer | Sell | $89K | 1,279at $69.57 | Sep 17, 2026 |
| Kumar NeilChief Executive Officer | Sell | $679K | 8,100at $83.86 | Aug 19, 2026 |
| Kumar NeilChief Executive Officer | Sell | $154K | 1,900at $81.15 | Aug 18, 2026 |
| Kumar NeilChief Executive Officer | Sell | $1.42M | 17,279at $82.21 | Aug 18, 2026 |
| Kumar NeilChief Executive Officer | Sell | $100K | 1,199at $83.77 | Aug 18, 2026 |
| Kumar NeilChief Executive Officer | Sell | $9K | 100at $85.65 | Aug 19, 2026 |
| Kumar NeilChief Executive Officer | Sell | $152K | 1,800at $84.69 | Aug 19, 2026 |
| Kumar NeilChief Executive Officer | Sell | $1.21M | 14,602at $82.99 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BBIO activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.